Current Opinion in Rheumatology, published by Lippincott Williams & Wilkins, stands as a vital resource in the field of rheumatology. Since its inception in 1989, this prestigious journal has been at the forefront of disseminating cutting-edge research, with a notable Q1 ranking in the 2023 Rheumatology category and an impressive Scopus rank of 7 out of 73, placing it in the 91st percentile. The journal's commitment to presenting insightful reviews and critical analyses of recent advancements and treatment strategies makes it an essential read for professionals, researchers, and students dedicated to the study of rheumatic diseases. Although not an open-access journal, Current Opinion in Rheumatology continues to foster an informed dialogue within the academic community through its high-impact content, ensuring that the latest developments and practices are accessible to those at the vanguard of rheumatology research.

BMC Rheumatology is a vital open-access journal that has been disseminating high-quality research in the field of rheumatology since its inception in 2017. Published by Springer Nature, this journal provides a platform for original research, reviews, and clinical studies that advance the understanding and treatment of rheumatic diseases. With a commendable impact factor and ranked in the second quartile (Q2) for Rheumatology as of 2023, BMC Rheumatology exemplifies expertise, contributing significantly to the medical community's dialogue. Researchers, professionals, and students will find valuable insights within its pages, as it caters to a diverse audience through its commitment to open-access publishing, facilitating knowledge sharing without barriers. Based in the United Kingdom and indexed in Scopus, the journal continues to thrive with a steady convergence of academic excellence through 2024, making it an indispensable resource for those dedicated to advancing rheumatological science.

Advances in Rheumatology is a premier open-access journal published by BMC, dedicated to advancing the field of rheumatology through high-quality, peer-reviewed research. Launched in 2018, the journal has quickly established itself within the academic community, achieving a commendable Q2 ranking in the category of Rheumatology as of 2023 and ranking #34 out of 73 in the Scopus Medicine Rheumatology listings, placing it in the 54th percentile. With a focus on innovative treatments, patient care, and the latest in rheumatological research, the journal provides a platform for researchers and clinicians to disseminate their findings and foster collaborative advancements in this critical area of medicine. Recognized for its accessibility, the journal follows an open-access model, ensuring that research is freely available to a global audience. With a commitment to high standards of academic rigor, Advances in Rheumatology plays a vital role in enhancing the understanding and treatment of rheumatic diseases, making it an invaluable resource for researchers, professionals, and students alike.

The International Journal of Rheumatic Diseases, published by WILEY, serves as a crucial platform for disseminating high-quality research and advancements in the field of rheumatology. With an ISSN of 1756-1841 and an E-ISSN of 1756-185X, this journal has established itself within the academic community since its inception in 2008, and it is set to continue until at least 2024. Positioned in the Q3 category of rheumatology, the journal holds a significant rank of #38 out of 73 in its field according to Scopus, showcasing its growing influence despite the competitive environment. The absence of Open Access reflects a traditional scholarly publishing model, allowing for meticulous peer-review processes to ensure the rigor and reliability of published studies. This journal aims to foster innovative research, critical reviews, and clinical studies, thereby contributing to a deeper understanding of rheumatic diseases and enhancing patient care. The dedicated readership, including researchers, healthcare professionals, and students, will find valuable insights into the latest findings and methodologies relevant to rheumatology in the journal's comprehensive articles.

Current Treatment Options in Rheumatology, published by SPRINGERNATURE, is a pivotal journal focused on advancing the field of rheumatology through the dissemination of cutting-edge research and comprehensive reviews. With an emphasis on current therapeutic strategies, this journal aims to provide healthcare professionals, researchers, and students with up-to-date information on the latest treatment modalities for rheumatic diseases. Although it operates under a subscription model, it offers a platform for sharing significant findings that can influence clinical practice and policy within the field of rheumatology. By promoting insightful discussions and collaborations, Current Treatment Options in Rheumatology plays a crucial role in shaping the future of rheumatic disease management and improving patient outcomes.

RMD Open, published by the BMJ Publishing Group, is a leading open-access journal that has made significant contributions to the fields of Immunology, Immunology and Allergy, and Rheumatology since its inception in 2015. With an impressive Q1 ranking in these categories for 2023, the journal has established itself as an essential platform for the dissemination of high-quality research, case studies, and reviews that advance understanding and treatment strategies in these critical areas of health. As an open-access publication, RMD Open ensures that its content is freely accessible to a global audience, promoting collaboration and knowledge sharing among researchers, clinicians, and students. Based in the United Kingdom at the British Medical Association House, RMD Open is not only dedicated to improving patient care but also to fostering innovative research and discussions in the rapidly evolving landscape of rheumatic diseases.

Rheumatology International, published by Springer Heidelberg, is a prestigious journal that focuses on innovative research in the field of rheumatology and immunology. Established in 1981, this peer-reviewed journal has contributed significantly to advancing our understanding of autoimmune disorders, clinical approaches, and therapeutic interventions. It holds a commendable Q2 ranking in the categories of Immunology, Immunology and Allergy, and Rheumatology as of 2023, showcasing its influence and importance within these disciplines. With a robust Scopus ranking—positioned 14 out of 73 in Medicine Rheumatology—it caters to a diverse audience of researchers, clinicians, and students committed to improving patient care and treatment modalities. Although it does not currently offer open access options, the journal remains a vital resource for insights on contemporary challenges and breakthroughs in rheumatological research, published from its base in Heidelberg, Germany.

Rheumatology & Autoimmunity, published by WILEY, is an emerging academic journal that delves into the intricacies of rheumatological diseases and autoimmune disorders, providing a critical platform for researchers and practitioners within the field. With an ISSN of 2767-1410 and E-ISSN 2767-1429, the journal aims to disseminate cutting-edge research in both clinical and laboratory settings, enhancing knowledge and understanding among professionals and scholars. Although currently classified in Q4 for Immunology and Allergy, and Q3 for Internal Medicine and Rheumatology as of 2023, the journal is positioned for growth and greater visibility in the scientific community. The three-year publishing span from 2021 to 2024 signifies a commitment to addressing contemporary issues and fostering collaboration among various disciplines related to immunology. As an open access journal, it provides wide accessibility, ensuring that groundbreaking research is available to a broad audience. This journal is poised to become a vital resource for those dedicated to advancing the understanding and treatment of autoimmune conditions.

Rheumatic Disease Clinics of North America is a premier journal published by W B Saunders Co-Elsevier Inc, dedicated to advancing the field of rheumatology through comprehensive and impactful research. With an ISSN of 0889-857X and an E-ISSN of 1558-3163, this esteemed publication has been disseminating knowledge since its inception in 1987, and continues to guide clinicians and researchers alike through its insightful articles and case studies. Positioned in the 2023 Q2 quartile for Rheumatology, it ranks #31 out of 73 journals in the Scopus category of Medicine _ Rheumatology, reflecting a commendable impact factor and relevance in the academic community. Although it does not offer open access options, the journal ensures that subscribers have access to cutting-edge research and reviews that address contemporary challenges and advancements in rheumatic disease. With its authoritative content, Rheumatic Disease Clinics of North America serves as a vital resource for those striving to improve patient care and clinical outcomes in the ever-evolving landscape of rheumatology research.

Acta Reumatologica Portuguesa is a premier open access journal dedicated to the field of rheumatology and general medicine, published by PUBLISAUDE-EDICOES MEDICAS LDA since its inception in 1973. Situated in Portugal, this journal aims to disseminate high-quality research findings, clinical studies, and reviews that contribute to the understanding and management of rheumatic diseases. Despite its current Q4 ranking in both Medicine (miscellaneous) and Rheumatology, it serves as a vital platform for researchers and professionals aiming to share innovative insights and clinical practices within a rapidly evolving field. Researchers and medical professionals will find valuable information that can significantly influence their work, given the journal’s commitment to accessible knowledge through its open access model. By prioritizing collaboration and knowledge-sharing, Acta Reumatologica Portuguesa continues to engage with issues of critical relevance in rheumatology, appealing to a diverse audience of scholars and healthcare practitioners.